Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Sellas Life Sciences Group Inc SLS

Healthcare Biotechnology
SELLAS Life Sciences Group, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the development of novel therapeutics for a range of cancer indications. The Company's product candidates, galinpepimut-S (GPS), a peptide immunotherapy directed against the Wilms tumor 1 (WT1), antigen, and SLS009, a selective small molecule cyclin-dependent kinase 9 (CDK9), inhibitor... see more

Recent & Breaking News (NDAQ:SLS)

SELLAS Announces Positive Follow-Up Phase 1/2 Clinical Data for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML)

GlobeNewswire February 26, 2020

SELLAS Life Sciences Provides Regulatory Update for Nelipepimut-S (NPS) for Triple Negative Breast Cancer (TNBC) Following FDA Feedback

GlobeNewswire February 14, 2020

SELLAS Announces Enrollment of First Patient in Phase 1 Trial of Galinpepimut-S (GPS) in Combination with Nivolumab (Opdivo®) in Patients with Malignant Pleural Mesothelioma (MPM)

GlobeNewswire February 11, 2020

SELLAS Names Dragan Cicic, MD, as Senior Vice President, Clinical Development

GlobeNewswire February 10, 2020

SELLAS Highlights Clinical Development Progress and Expected 2020 Milestones

GlobeNewswire January 13, 2020

SELLAS Announces Pricing of $6.5 Million Registered Direct Offering Priced At-The-Market

GlobeNewswire January 9, 2020

SELLAS Commences Pivotal Phase 3 REGAL Study of Galinpepimut-S (GPS) in Patients with Acute Myeloid Leukemia (AML)

GlobeNewswire January 8, 2020

SELLAS to Present at Biotech Showcase(TM)

GlobeNewswire January 6, 2020

SELLAS to Present at the 12th Annual LD Micro Main Event

GlobeNewswire December 4, 2019

SELLAS Life Sciences Provides Business Update and Reports Third Quarter 2019 Financial Results

GlobeNewswire November 14, 2019

SELLAS to Host R&D Investor Event on Galinpepimut-S (GPS) and the Next Generation of Cancer Immunotherapy

GlobeNewswire November 8, 2019

SELLAS Announces Reverse Stock Split

GlobeNewswire November 6, 2019

SELLAS Life Sciences Provides Business Update and Reports Second Quarter 2019 Financial Results

GlobeNewswire August 14, 2019

SELLAS Announces Completion of Enrollment in Randomized Phase 2 VADIS Trial of Nelipepimut-S (NPS) in Women with Ductal Carcinoma In Situ (DCIS) of the Breast

GlobeNewswire August 5, 2019

SELLAS Advances Galinpepimut-S (GPS) in Combination with KEYTRUDA® (pembrolizumab) Program with Dosing of First Patient in Phase 1/2 Basket Study

GlobeNewswire July 31, 2019

SELLAS Life Sciences Announces Closing of $15 Million Public Offering

GlobeNewswire June 18, 2019

SELLAS Life Sciences Announces Pricing of $15 Million Public Offering

GlobeNewswire June 14, 2019

SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019

GlobeNewswire June 3, 2019

SELLAS Life Sciences Provides Business Update and Reports First Quarter 2019 Financial Results

GlobeNewswire May 15, 2019

SELLAS Life Sciences Group and World-Renowned Cancer Center to Study Galinpepimut-S (GPS) in Combination with Nivolumab in Patients with Malignant Pleural Mesothelioma (MPM)

GlobeNewswire April 4, 2019